Drug intelligence / Profile preview

IDC114

Development stage: Preclinical
Lead developer: Prestige Biopharma Innovative Discovery Centre
Administration: Subcutaneous

Overview

IDC114 is a first-in-class therapeutic candidate being developed by Prestige Biopharma IDC. It is currently in the preclinical stage of development. The drug is being investigated for potential applications in immunology, cardiovascular diseases, and solid tumors. While specific target and mechanism of action details have not been publicly disclosed, it is part of Prestige Biopharma's innovative pipeline, which focuses on novel antibody-based therapies and first-in-class biologics.

Beyond the preview

Go deeper on IDC114.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IDC114.

Explore the full profile